AK9

AK9 is an adenylate kinase that maintains local nucleotide and energy homeostasis in motile ciliated and flagellated cells (PMID:23416111, PMID:37812723). Biochemically, recombinant AK9 phosphorylates AMP, dAMP, CMP, and dCMP using ATP or GTP as phosphate donor and additionally exhibits nucleoside diphosphate kinase activity, generating tri-phosphates from the corresponding diphosphates (PMID:23416111). In sperm, bi-allelic loss-of-function in humans and Ak9 knockout in mice cause asthenozoospermia, immotile sperm, depleted ATP, abnormal flagellar ultrastructure, and infertility, establishing AK9 as essential for sperm nucleotide metabolism, motility, hyperactivation, and zona pellucida penetration (PMID:37713809, PMID:37812723). Mechanistically, AK9 localizes to the flagellar axoneme via the head of radial spoke 3 (RSP3) and cooperates with AK8 as an adenylate kinase phosphate energy shuttle that transfers ATP to sites of high energy consumption (PMID:38761355). The same activity supports ependymal cilia: an AK9 mutation reduces ciliary beat frequency without altering cilia structure and produces communicating hydrocephalus, with damaging heterozygous variants enriched in idiopathic normal pressure hydrocephalus patients (PMID:38100419).

1. 2013 High

   Established the core enzymatic identity of AK9 by defining which nucleotide substrates and phosphate donors it uses, answering what biochemical reaction this previously uncharacterized kinase catalyzes.

   Evidence Recombinant expression in E. coli with in vitro enzymatic assays and kinetic parameter determination

   PMID:23416111

   Open questions at the time

   • No cellular or tissue context for the activity
   • Physiological substrate preference in vivo not addressed
   • No structural model of the active site
2. 2014 Medium

   Placed AK9 within the broader adenylate kinase isoenzyme family and noted its potential to activate nucleoside analogue prodrugs, framing its biochemistry in a pharmacological context.

   Evidence Review consolidating prior in vitro biochemical characterization

   PMID:24495878

   Open questions at the time

   • No new experimental data
   • Nucleoside analogue activation not demonstrated in cells
   • Tissue-specific role unresolved
3. 2016 Medium

   First in vivo disease link, identifying an AK9 splicing mutation as a modifier of congenital myasthenic syndrome and proposing nucleotide deficiency impairs N-glycosylation.

   Evidence Homozygosity mapping, whole-exome and Sanger sequencing, splicing analysis in patients

   PMID:27966543

   Open questions at the time

   • N-glycosylation mechanism is proposed but not experimentally demonstrated
   • No functional assay of mutant AK9 enzyme activity
   • Modifier effect not modeled in animals
4. 2023 High

   Connected AK9 enzymatic activity to a physiological requirement by showing loss-of-function depletes sperm nucleotide pools and impairs glycolysis, causing asthenozoospermia.

   Evidence Patient whole-exome sequencing, CRISPR Ak9-knockout mice, electron microscopy, LC-MS adenosine detection, targeted sperm metabolomics

   PMID:37713809

   Open questions at the time

   • Subcellular localization within sperm not resolved here
   • Direct link between AK9 activity and glycolytic enzymes not defined
   • Binding partners unidentified
5. 2023 High

   Independently confirmed AK9 essentiality for sperm motility across species and tied the phenotype to ATP levels and axonemal ultrastructure, establishing a flagellar energy role.

   Evidence Bovine whole-genome and testis RNA sequencing, Ak9-knockout mice, sperm motility and ATP assays, electron microscopy, IVF/AI fertility tests

   PMID:37812723

   Open questions at the time

   • Molecular tethering of AK9 to the axoneme not yet shown
   • Distinction between hyperactivation and basal motility defects unresolved
   • No structural basis for axonemal localization
6. 2023 High

   Extended AK9 function to ependymal cilia, showing its activity sets ciliary beat frequency and that mutations cause communicating hydrocephalus, linking the energy-shuttle role to brain fluid dynamics.

   Evidence Patient sequencing, knock-in and heterozygous mouse models, cilia beat frequency measurement, behavioral testing, brain imaging

   PMID:38100419

   Open questions at the time

   • Cilia structure unaffected, so the precise step requiring AK9 within beating is undefined
   • Mechanism connecting nucleotide shuttle to motor activity not detailed
   • Dose dependence of heterozygous phenotype incomplete
7. 2023 Medium

   Implicated AK9 as a tumor suppressor in lung cancer regulated by m6A modification, broadening its role beyond ciliary biology.

   Evidence MeRIP-qPCR for m6A, in vitro functional assays in lung cancer cell lines, TCGA expression analysis

   PMID:38051288

   Open questions at the time

   • Single-lab in vitro evidence without in vivo tumor model
   • Mechanism connecting AK9 enzymatic activity to growth suppression not defined
   • m6A reader/writer mediating the effect unidentified
8. 2024 High

   Resolved how AK9 is positioned to act in the flagellum, identifying RSP3 as the axonemal adapter and demonstrating cooperative ATP transfer with AK8 as a phosphate energy shuttle.

   Evidence Reciprocal immunoprecipitation-mass spectrometry, ATP probe assay, metabolomics in knockout mouse models

   PMID:38761355

   Open questions at the time

   • Stoichiometry and structure of the AK8/AK9/RSP3 assembly unknown
   • Whether RSP3 adapter mechanism applies in ependymal cilia untested
   • Directionality and regulation of the shuttle not fully characterized

• How AK9's enzymatic activity is mechanistically coupled to dynein motor function and beat frequency, and whether its tumor-suppressor and ciliary roles share a common nucleotide-homeostasis basis, remain unresolved.
• No structural model of AK9 or its axonemal complex
• Mechanism linking nucleotide shuttle to motor force generation undefined
• Unified mechanism across reproductive, ciliary, and oncogenic contexts not established